Volm M, Efferth T, Günther A, Lathan B
Institute of Experimental Pathology, German Cancer Research Center, Heidelberg.
Arzneimittelforschung. 1987 Jul;37(7):862-7.
Doxorubicin (adriamycin) preconditioned S180 cells were more resistant to doxorubicin. The resistance was detected by three different methods (short-term test, colony assay, tissue culture assay). The doxorubicin-resistant S180 cells express the pleitrop drug resistance phenotype. There exists a multidrug resistance to doxorubicin, dactinomycin (actinomycin D), vincristine and colchicine. In addition, collateral sensitivity was found to fluorouracil (5-fluorouracil) and methotrexate. This multidrug phenotype is in accordance with the pleiotropic phenotype of colchicine-resistant CHO cells. Resistant S180 cells express a glycoprotein of Mr 170 kd determined by indirect immunofluorescence using a monoclonal antibody (Mab 265/F4) to the P-glycoprotein of colchicine-resistant CHO-cells. The P-glycoprotein could be an important prognostic factors for tumors with multidrug resistance.
阿霉素（阿德里亚霉素）预处理的S180细胞对阿霉素更具抗性。通过三种不同方法（短期试验、集落测定、组织培养测定）检测到这种抗性。阿霉素抗性S180细胞表达多药耐药表型。对阿霉素、放线菌素D、长春新碱和秋水仙碱存在多药耐药性。此外，还发现对氟尿嘧啶（5-氟尿嘧啶）和甲氨蝶呤有旁系敏感性。这种多药表型与秋水仙碱抗性CHO细胞的多效表型一致。抗性S180细胞表达一种170kd的糖蛋白，该糖蛋白是使用针对秋水仙碱抗性CHO细胞P-糖蛋白的单克隆抗体（Mab 265/F4）通过间接免疫荧光法测定的。P-糖蛋白可能是多药耐药肿瘤的一个重要预后因素。
